Bradley Alexander McGregor MD

Genitourinary Oncology, Hematologic Oncology

Physician

450 Brookline AveBoston, MA 02215
Phone+1 617-632-6328

Dr. McGregor is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McGregor's full profile Already have an account?

Summary

Dr. Bradley McGregor is an oncologist in Boston, MA and is affiliated with Dana-Farber Cancer Institute. He received his medical degree from Tufts University School of Medicine and has been in practice 13 years. He specializes in genitourinary oncology and hematologic oncology.

Education & Training

San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 2007 - 2010
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 2004 - 2007
Tufts University School of MedicineClass of 2004

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2012 - Present
FL State Medical License 2022 - Present
ME State Medical License 2022 - 2028
RI State Medical License 2022 - 2028
CT State Medical License 2022 - 2027
MA State Medical License 2016 - 2027
NH State Medical License 2023 - 2027
OH State Medical License 2022 - 2026
VT State Medical License 2022 - 2026
VA State Medical License 2006 - 2012
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Start of enrollment: 2017 Dec 28
ACTIVE_NOT_RECRUITING
PHASE2
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression Start of enrollment: 2019 Nov 27
WITHDRAWN
PHASE2

Publications & Presentations

PubMed

Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.
Niki M Zacharias, Eric S Rupe, Xinyue Chen, Ritesh R Kotecha, Damian T Rieke
Clinical Cancer Research. 2026-08-21
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
Rana R McKay, Karla V Ballman, Pamela J Atherton, Archana Ajmera, Tareq Al Baghdadi
Journal of Clinical Oncology. 2026-08-20
Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Toni K Choueiri, Jaime Merchán, Amita Patnaik, Alexandra Drakaki, Brian I Rini
Nature. 2026-08-01

Journal Articles

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma
Praful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology

Lectures

Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH).
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020

Press Mentions

Immune Checkpoint Add-Ons to BCG: No Slam DunkOctober 24th, 2025
ASCO Updates Guidelines for Metastatic Castration-Resistant Prostate CancerJune 16th, 2025
“Unprecedented” Data Reinforce First-Line Enfortumab Vedotin Combo for Advanced Bladder CancerFebruary 19th, 2025